Barclays Cuts Centene (NYSE:CNC) Price Target to $91.00

by · The Cerbat Gem

Centene (NYSE:CNC – Free Report) had its target price lowered by Barclays from $97.00 to $91.00 in a research note issued to investors on Tuesday morning, Benzinga reports. Barclays currently has an overweight rating on the stock.

CNC has been the subject of a number of other research reports. TD Cowen increased their price target on shares of Centene from $80.00 to $89.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Jefferies Financial Group cut Centene from a “buy” rating to a “hold” rating and dropped their price target for the company from $83.00 to $69.00 in a research report on Wednesday, July 24th. StockNews.com downgraded Centene from a “strong-buy” rating to a “buy” rating in a research note on Monday. Oppenheimer cut their price target on Centene from $110.00 to $95.00 and set an “outperform” rating for the company in a research note on Monday, July 29th. Finally, Robert W. Baird lowered their price objective on shares of Centene from $83.00 to $66.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $84.00.

Check Out Our Latest Stock Analysis on Centene

Centene Trading Up 0.8 %

NYSE:CNC opened at $62.26 on Tuesday. The company has a quick ratio of 1.17, a current ratio of 1.10 and a debt-to-equity ratio of 0.64. Centene has a 52-week low of $59.77 and a 52-week high of $81.42. The stock’s 50 day moving average price is $71.55 and its 200 day moving average price is $72.02. The company has a market capitalization of $32.75 billion, a PE ratio of 10.81, a P/E/G ratio of 0.85 and a beta of 0.48.

Institutional Trading of Centene

Institutional investors have recently bought and sold shares of the company. EP Wealth Advisors LLC increased its holdings in Centene by 1.0% during the 1st quarter. EP Wealth Advisors LLC now owns 13,604 shares of the company’s stock valued at $1,068,000 after acquiring an additional 133 shares in the last quarter. WR Wealth Planners LLC raised its position in shares of Centene by 41.4% during the 2nd quarter. WR Wealth Planners LLC now owns 468 shares of the company’s stock worth $31,000 after purchasing an additional 137 shares during the last quarter. Whittier Trust Co. lifted its stake in Centene by 10.0% in the 2nd quarter. Whittier Trust Co. now owns 1,562 shares of the company’s stock valued at $104,000 after buying an additional 142 shares in the last quarter. Fidelis Capital Partners LLC increased its position in Centene by 5.0% during the first quarter. Fidelis Capital Partners LLC now owns 3,316 shares of the company’s stock worth $260,000 after buying an additional 158 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC raised its holdings in shares of Centene by 2.1% in the third quarter. Mount Yale Investment Advisors LLC now owns 8,082 shares of the company’s stock worth $608,000 after acquiring an additional 167 shares during the last quarter. 93.63% of the stock is currently owned by hedge funds and other institutional investors.

About Centene

(Get Free Report)

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children’s health insurance program, foster care, medicare-medicaid plans, long-term services and support.

Recommended Stories